Massive bleeding from a gastric artery pseudoaneurysm in hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A case report
作者机构：Department of Interventional RadiologyShenzhen Traditional Chinese Medicine HospitalShenzhen 518033Guangdong ProvinceChina Department of HepatologyShenzhen Traditional Chinese Medicine HospitalShenzhen 518033Guangdong ProvinceChina
出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)
年 卷 期：2023年第15卷第6期
页 面：1232-1239页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Atezolizumab Bevacizumab Hepatocellular carcinoma Gastric artery pseudoaneurysm Gastrointestinal bleeding Case report
摘 要：BACKGROUND The combination of atezolizumab(ATZ)and bevacizumab(BVZ)was approved as first-line systemic therapy for advanced hepatocellular carcinoma(HCC)owing to its superior rates of response and patient ***,ATZ+BVZ is associated with increased risk of upper gastrointestinal(GI)bleeding,including arterial bleeding,which is rare and potentially *** present a case of massive upper GI bleeding from a gastric pseudoaneurysm in a patient with advanced HCC who had been treated with ATZ+*** SUMMARY A 67-year-old man presented with severe upper GI bleeding after atezolizumab(ATZ)+bevacizumab(BVZ)therapy for *** failed to detect the bleeding *** subtraction angiography revealed a gastric artery pseudoaneurysm and contrast extravasation from the inferior splenic artery and a branch of the left gastric *** hemostasis was achieved with *** HCC patients who have been treated with ATZ+BVZ should be followed for 3 to 6 mo to monitor for development of massive GI *** may require *** is an effective treatment.
维普期刊数据库